IL-17A has been proposed to promote the maintenance of intestinal epithelial cell integrity based on observations that IL-17A inhibition exacerbates colitis in a mouse model, which leads to weakening of the intestinal epithelial barrier (64). Here, IL17A is linked to colitis.